LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

LLY

1,128.17

+3.92%↑

JNJ

231.2

-0.07%↓

ABBV

218.55

+1.45%↑

UNH

382.4

-0.44%↓

MRK

119.96

-0.33%↓

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

11.13 -4.38

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

10.8

Máximo

11.64

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	4.522 50.102
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+43.34% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.1B
Apertura anterior	15.51
Cierre anterior	11.13

Noticias sobre sentimiento de mercado

By Acuity

10%

90%

7 / 344 Clasificación en Healthcare

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 may 2026, 21:33 UTC

Ganancias

Correction to Salesforce 1Q Sales, Profit Rise Article

27 may 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 may 2026, 20:18 UTC

Ganancias

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 may 2026, 23:49 UTC

Charlas de Mercado

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 may 2026, 23:39 UTC

Charlas de Mercado

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 may 2026, 23:34 UTC

Charlas de Mercado

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 may 2026, 23:34 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

27 may 2026, 23:08 UTC

Charlas de Mercado

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 may 2026, 22:21 UTC

Charlas de Mercado

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 may 2026, 21:29 UTC

Acciones populares

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 may 2026, 21:08 UTC

Ganancias

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 may 2026, 21:02 UTC

Ganancias

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 may 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 may 2026, 20:55 UTC

Ganancias

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 may 2026, 20:48 UTC

Ganancias

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 may 2026, 20:45 UTC

Ganancias

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 may 2026, 20:34 UTC

Adquisiciones, fusiones, absorciones

Webster Financial Stockholders Approve Sale to Banco Santander

27 may 2026, 20:32 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 may 2026, 20:32 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 may 2026, 20:32 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 may 2026, 20:30 UTC

Ganancias

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 may 2026, 20:30 UTC

Adquisiciones, fusiones, absorciones

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 may 2026, 20:22 UTC

Ganancias

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 may 2026, 20:16 UTC

Ganancias

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 may 2026, 20:13 UTC

Ganancias

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 may 2026, 20:13 UTC

Ganancias

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 may 2026, 20:13 UTC

Ganancias

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 may 2026, 20:12 UTC

Ganancias

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 may 2026, 20:12 UTC

Ganancias

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

43.34% repunte

Estimación a 12 Meses

Media 16.8 USD 43.34%

Máximo 20 USD

Mínimo 13.6 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Sentimiento

By Acuity

7 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.